Manufacturers report sintilimab plus gemcitabine and platinum chemotherapy combination hits primary endpoint in locally advanced or metastatic squamous non-small cell lung cancer study

In the ORIENT-12 trial (n=357), this combination treatment including sintilimab, an anti-PD-1 antibody improved progression free survival vs gemcitabine and platinum chemotherapy alone

Source:

Biospace Inc.